312 related articles for article (PubMed ID: 16123131)
1. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
[TBL] [Abstract][Full Text] [Related]
2. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
3. Targeted proapoptotic anticancer drug delivery system.
Chandna P; Saad M; Wang Y; Ber E; Khandare J; Vetcher AA; Soldatenkov VA; Minko T
Mol Pharm; 2007; 4(5):668-78. PubMed ID: 17685579
[TBL] [Abstract][Full Text] [Related]
4. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.
Dharap SS; Chandna P; Wang Y; Khandare JJ; Qiu B; Stein S; Minko T
J Pharmacol Exp Ther; 2006 Mar; 316(3):992-8. PubMed ID: 16291730
[TBL] [Abstract][Full Text] [Related]
6. Targeted proapoptotic LHRH-BH3 peptide.
Dharap SS; Minko T
Pharm Res; 2003 Jun; 20(6):889-96. PubMed ID: 12817893
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.
Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H
Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.
Shah V; Taratula O; Garbuzenko OB; Taratula OR; Rodriguez-Rodriguez L; Minko T
Clin Cancer Res; 2013 Nov; 19(22):6193-204. PubMed ID: 24036854
[TBL] [Abstract][Full Text] [Related]
10. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
[TBL] [Abstract][Full Text] [Related]
11. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Saad M; Garbuzenko OB; Ber E; Chandna P; Khandare JJ; Pozharov VP; Minko T
J Control Release; 2008 Sep; 130(2):107-14. PubMed ID: 18582982
[TBL] [Abstract][Full Text] [Related]
12. LHRH-Targeted Drug Delivery Systems for Cancer Therapy.
Li X; Taratula O; Taratula O; Schumann C; Minko T
Mini Rev Med Chem; 2017; 17(3):258-267. PubMed ID: 27739358
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
15. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
16. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
17. Novel polymeric prodrug with multivalent components for cancer therapy.
Khandare JJ; Chandna P; Wang Y; Pozharov VP; Minko T
J Pharmacol Exp Ther; 2006 Jun; 317(3):929-37. PubMed ID: 16469865
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
Dharap SS; Qiu B; Williams GC; Sinko P; Stein S; Minko T
J Control Release; 2003 Aug; 91(1-2):61-73. PubMed ID: 12932638
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
He Y; Zhang L; Song C
Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
